Acquired coagulation inhibitors result in immune-mediated clearance or inhibition of a coagulation factor. While most inhibitors are directed against factor VIII (FVIII), they can develop against any coagulation factor. Since the previous guideline in 2013, new data have been published in relation to acquired FVIII inhibitors and some of the rarer coagulation factor inhibitors, necessitating an update.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this good practice paper. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.